ArticleCell reports2022
Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Resolution and Quantitation of Ribonucleosides and Deoxyribonucleosides in Digested Genomic DNA by UHPLC-MS/MS.Biomedical chromatography : BMC · 2026Article
- ATR kinase inhibitors induce mitochondrial fission in CD8bioRxiv : the preprint server for biology · 2026Article
- OCT4 enhances the firing efficiency of late DNA replication origins in mouse embryonic stem cells.Nature communications · 2026Article
- Article
- Replication-associated base excision repair/single-strand break repair regulates PARG inhibitor response via the PRMT1/PRMT5/ATR axis.NAR cancer · 2025Article
- Nuclear DAB2IP regulates DNA replication initiation through activating PLK1-mediated HBO1 phosphorylation.Nucleic acids research · 2025Article
- Decoding nucleoside supplementation: how thymidine outperforms ribonucleosides in accelerating mammalian replication forks.Nucleic acids research · 2025Article
- ATR promotes mTORC1 activity via de novo cholesterol synthesis.EMBO reports · 2025Article
- The cold immunological landscape of ATM-deficient cancers.Journal for immunotherapy of cancer · 2025Article
- Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).Cancer chemotherapy and pharmacology · 2025Article
- Utilizing Flaxseed as an Antimicrobial Alternative in Chickens: Integrative Review forCurrent issues in molecular biology · 2024Review
- ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation.JCI insight · 2024Article
- The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.Nature communications · 2024Article
- Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer.JCI insight · 2024Article
- ATR kinase supports normal proliferation in the early S phase by preventing replication resource exhaustion.Nature communications · 2023Article
- The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy.JCI insight · 2023Article
- An orally available cancer drug AZD6738 prevents type 1 diabetes.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Norie SugitaniDepartment of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Frank P VendettiDepartment of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Andrew J CiprianoDepartment of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Pinakin PandyaDepartment of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Joshua J DeppasDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
Tatiana N MoiseevaTallinn University of Technology, Department of Chemistry and Biotechnology, Tallinn, Estonia.
Sandra Schamus-HaynesDepartment of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Yiyang WangDepartment of Immunology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Drake PalmerUPMC Hillman Cancer Center, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Hatice U OsmanbeyogluUPMC Hillman Cancer Center, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Biomedical Informatics, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Anna BostwickDepartment of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Center for Metabolic Disease Research, Philadelphia, PA, USA.
Nathaniel W SnyderDepartment of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Center for Metabolic Disease Research, Philadelphia, PA, USA.
Yi-Nan GongDepartment of Immunology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Katherine M AirdUPMC Hillman Cancer Center, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Greg M DelgoffeDepartment of Immunology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jan H BeumerDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Division of Hematology-Oncology, UPMC Hillman Cancer Center, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Christopher J BakkenistDepartment of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: bakkenistcj@upmc.edu.
UPMC Hillman Cancer Center · USTemple University · USUniversity of Pittsburgh · USTallinn University of Technology · EE
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MInvestigating p16 Loss in Pro-tumorigenic MetabolismR37CA240625 · NCI · WISTAR INSTITUTE · PI AIRD, KATHERINE MARIE · 2020 to 2025
$2.6MMetabolic control of regulatory T cell functional identityR01AI171483 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2022 to 2025
$2.4MThe Impact of ATR Kinase Inhibitors on CD8+ T Cell Expansion and Memory DevelopmentR01CA266172 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2022 to 2026
$2.3MExploring and exploiting metabolic plasticity in regulatory T cellsDP2AI136598 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DELGOFFE, GREG M. · 2017 to 2017
$2.3MNecrotic survivors and plasma membrane integrity signalingDP2GM146320 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GONG, YI-NAN · 2021 to 2024
$2.3MDNA damage signaling to immune checkpointsR01CA204173 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAKKENIST, CHRISTOPHER J. · 2017 to 2021
$1.8MCancer Pharmacokinetics Research SpecialistR50CA211241 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARISE, ROBERT · 2016 to 2025
$1.8MDNA damage signaling to dormant origins of replicationR01CA236367 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAKKENIST, CHRISTOPHER J. · 2020 to 2024
$1.8MAlgorithms to link signaling pathways with transcriptional programs for precision medicineR00CA207871 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI OSMANBEYOGLU, HATICE ULKU · 2019 to 2022
$738kCRL3KEAP1 complex licenses genotoxic stress-induced tumor cell deathR21CA259457 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GONG, YI-NAN · 2021 to 2022
$380kNCI NIH HHS P30 CA047904NCI NIH HHS R00 CA207871NCI NIH HHS R01 CA204173NCI NIH HHS R01 CA236367NCI NIH HHS R01 CA266172NCI NIH HHS R21 CA259457NCI NIH HHS R37 CA240625NCI NIH HHS R50 CA211241NIAID NIH HHS DP2 AI136598NIAID NIH HHS R01 AI171483NIGMS NIH HHS DP2 GM146320
Abstract
ATR kinase is a central regulator of the DNA damage response (DDR) and cell cycle checkpoints. ATR kinase inhibitors (ATRi's) combine with radiation to generate CD8
Indexed as
CD8-Positive T-LymphocytesCDC2 Protein KinaseAnimalsAtaxia Telangiectasia Mutated ProteinsCell DeathCell Line, TumorDeoxyuridineDNADNA DamageDNA-Directed DNA PolymeraseGenomicsInterferon-alphaInterferon-betaMiceNucleotidesProtein Kinase InhibitorsAtaxia Telangiectasia Mutated ProteinsCDC2 Protein KinaseDeoxyuridineDNADNA-Directed DNA PolymeraseInterferon-alphaInterferon-betaNucleotidesProtein Kinase InhibitorsRNAThymidineATR/origin firing/deoxyuridine contamination/IFN-α/βCP: CancerCP: Immunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.